Skip to content
Screener

Travere Therapeutics, Inc. TVTX Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.26B+5.4%
Vera Therapeutics logo
Vera TherapeuticsVERA
$1.86M
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$3.54M-14.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.85M-10.9%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$15.54M+132%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$2.09M-37.1%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042
AssetsMarch 31, 2026 / (unaudited)December 31, 2025
Total current liabilities125,437159,904
Convertible debt312,079311,724
Operating lease liabilities, less current portion9,56611,134
Other non-current liabilities9,3787,601
Total liabilities456,460490,363
Commitments and Contingencies (See Note 13)
Stockholders' Equity:
Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s other non-current liabilities?
Travere Therapeutics, Inc. (TVTX) reported other non-current liabilities of $9.38M in Q1 2026.
How has Travere Therapeutics, Inc.'s other non-current liabilities changed year-over-year?
Travere Therapeutics, Inc.'s other non-current liabilities increased by 28.9% year-over-year, from $7.27M to $9.38M.
What is the long-term trend for Travere Therapeutics, Inc.'s other non-current liabilities?
Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s other non-current liabilities has grown at a -9.0% compound annual growth rate (CAGR), from $12.19M to $7.6M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about Travere Therapeutics, Inc.'s other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude